Ocugen Rally Ends; Shares Slip 11%

Shares of biotechnology company Ocugen, Inc. (OCGN) shares are down 11 percent on Wednesday's trading thus breaking the stock's upward trend since the past few days. The stock has been on an upward trajectory since submitting NDA for Phase 3 clinical trial of its COVID-19 vaccine candidate COVAXIN (BBV152) on October 26.

Currently at $13.92, the stock has traded between $0.27 and $18.77 during the past 52 weeks.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Follow RTT